BTAI
Bioxcel Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.46 / 10
Netural
Fund flow metrics are mixed but generally positive, scoring 7.73/10. While overall and block flows show a slight negative trend, the inflow ratios (e.g., 0.484 for blocks) indicate active trading and potential accumulation. Analyst sentiment is neutral, with a weighted rating of 1.19 and a distribution of Strong Buy (66.7%) and Neutral (33.3%), yet historical win rates are low (20.0% for HC Wainwright), limiting conviction.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-09-12
InstitutionMizuho
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for BTAI?
- BTAI holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.46/10 (Netural).
